ICPT News and Press, Intercept Pharmaceuticals Inc. From 09/26/23

2023-09-26 16:29:38 ET More on Intercept Pharma Seeking Alpha’s Quant Rating on Intercept Pharma Intercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All Parties Intercept: Narrowed Market, Concentrated Strategy (Rating Upgrade) ...

2023-09-26 15:35:33 ET Summary Intercept Pharmaceuticals, the developer of liver disease drug Ocaliva, has agreed to be acquired by Italian Pharma company Alfasigma in an all-cash deal worth approximately $800 million. Intercept faced challenges securing approval for Ocaliva to tr...

2023-09-26 14:17:26 ET Shares of Intercept Pharmaceuticals (NASDAQ: ICPT) are seeing explosive gains in Tuesday's trading following an announcement that the company is on track to be acquired by Alfasigma, a private Italian pharmaceuticals company. Intercept's share price was up...

2023-09-26 13:46:32 ET Gainers: Soleno Therapeutics ( SLNO ) +446% . Femasys ( FEMY ) +271% . Immunovant ( IMVT ) +101% . Intercept Pharmaceuticals ( ICPT ) +79% . Acasti Pharma ( ACST ) +35% . Applied Therapeutics ( APLT ...

2023-09-26 12:15:20 ET DENVER, Colo., Sept 26, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Soleno Therapeutics (NASDAQ: SLNO), Femasys (NASDAQ: FEMY), Immunovant (NASDAQ: IMVT), Bullfrog AI (NA...

MONSEY, N.Y., Sept. 26, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”) to Alfasigma for $19.00 per share in cash. If you remain an Intercept sha...

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) is one of today's top gainers. The company's shares are currently up 78.35% on the day to $18.62. Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive n...

2023-09-26 09:01:36 ET More on Intercept Seeking Alpha’s Quant Rating on Intercept Pharma Historical earnings data for Intercept Pharma Intercept: Narrowed Market, Concentrated Strategy (Rating Upgrade) Intercept Pharma beats Q2 top and bottom line est...

Proposed all-cash acquisition will materially expand Alfasigma’s portfolio in gastroenterology and hepatology and its presence in the U.S. market Transaction price represents an 82% premium to Intercept’s closing price on September 25, 2023 Alfasigma adds Ocaliva®, the ...

2023-09-20 11:55:57 ET More on Health Care Sector: Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth consecutiv...